



DECLARATION

I, Emiko Oku of HIROTA & ASSOCIATES, residing at Wakabayashi Bldg. 3F, 8-5, Akasaka 2-chome, Minato-ku, Tokyo 107-0052, Japan, do hereby certify that I am conversant with the English and Japanese languages and am a competent translator thereof, and I further certify that to the best of my knowledge and belief the following is a true and correct translation made by me of the document in the Japanese language filed for a patent application in Japan under No. 11-240642 on August 27, 1999 in the name of JAPAN SCIENCE AND TECHNOLOGY CORPORATION in Tokyo, Japan, entitled: "HIGH-AFFINITY CHOLINE TRANSPORTER".

Signed this 29 day of August, 2006

A handwritten signature in cursive script, appearing to read "Emiko Oku", written over a horizontal line.

Emiko Oku



**PATENT OFFICE
JAPANESE GOVERNMENT**

This is to certify that the annexed is a true copy of the following application as filed with this Office.

Date of Application: August 27, 1999

Application Number: Patent Application No.11-240642

Applicant(s): JAPAN SCIENCE AND TECHNOLOGY
CORPORATION

Commissioner, Kozo Oikawa (Sealed)
Patent Office

[Name of Document]	Patent Application
[Case Number]	A011P12
[Filing Date]	August 27, 1999
[Addressee]	Commissioner of Patent Office
[International Classification]	C12N 15/00
[Inventor]	
[Address or Residence]	Room 411, 3-1, Numama 2-chome, Zushi-shi, Kanagawa
[Name]	Tatsuya HAGA
[Inventor]	
[Address or Residence]	Room 101, Rizu Hibarigaoka, 1-6, Hibarigaokakita 4-chome, Hoya-shi, Tokyo
[Name]	Takashi OKUDA
[Applicant for Patent]	
[Code Number]	396020800
[Name or Corporation Name]	JAPAN SCIENCE AND TECHNOLOGY CORPORATION
[Representative]	Moritaka NAKAMURA
[Agent]	
[Code Number]	100107984
[Patent Attorney]	
[Name or Corporation Name]	Masanori HIROTA
[Indication of Fee]	
[Deposit Account Number]	044347
[Amount of Payment]	21,000 yen
[List of Filed Documents]	
[Name of Document]	Specification 1
[Name of Document]	Drawing 1
[Name of Document]	Abstract 1

[Confirmation of Proof]

Proof Necessary

[Name of Document] SPECIFICATION

[Title of the Invention] HIGH-AFFINITY CHOLINE TRANSPORTER

[Scope of Claims]

[Claim 1] A gene which encodes a protein (a) or (b) described below;

(a) a protein comprising an amino acid sequence represented by Seq. ID No. 2,

(b) a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.2, and having high-affinity choline transporter activity.

[Claim 2] DNA containing a base sequence represented by Seq. ID No. 1 or its complementary sequence and a part or a whole of these sequences.

[Claim 3] DNA derived from a nematode which hybridizes with DNA according to claim 2 under a stringent condition, and encodes a protein having high-affinity choline transporter activity.

[Claim 4] A gene which encodes a protein (a) or (b) described below;

(a) a protein comprising an amino acid sequence represented by Seq. ID No. 4,

(b) a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.4, and having high-affinity choline transporter activity.

[Claim 5] DNA containing a base sequence represented by Seq. ID No. 3 or its complementary sequence and a part or a whole of these sequences.

[Claim 6] DNA derived from a rat which hybridizes with DNA comprising a gene according to claim 5 under a stringent condition,

and encodes a protein having high-affinity choline transporter activity.

[Claim 7] A gene which encodes a protein (a) or (b) described below;

(a) a protein comprising an amino acid sequence represented by Seq. ID No. 6,

(b) a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.6, and having high-affinity choline transporter activity.

[Claim 8] DNA containing a base sequence represented by Seq. ID No. 5 or its complementary sequence and a part or a whole of these sequences.

[Claim 9] DNA derived from a human which hybridizes with DNA comprising a gene according to claim 8 under a stringent condition, and encodes a protein having high-affinity choline transporter activity.

[Claim 10] A protein comprising an amino acid sequence represented by Seq. ID No. 2 and having nematode high-affinity choline transporter activity.

[Claim 11] A protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.2, and having nematode high-affinity choline transporter activity.

[Claim 12] A protein comprising an amino acid sequence represented by Seq. ID No. 4 and having rat high-affinity choline transporter activity.

[Claim 13] A protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.4, and having

rat high-affinity choline transporter activity.

【Claim 14】 A protein comprising an amino acid sequence represented by Seq. ID No. 6 and having human high-affinity choline transporter activity.

【Claim 15】 A protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No. 6, and having human high-affinity choline transporter activity.

【Claim 16】 An antibody that specifically binds to the protein having nematode high-affinity choline transporter activity according to claim 10 or 11.

【Claim 17】 An antibody that specifically binds to the protein having rat high-affinity choline transporter activity according to claim 12 or 13.

【Claim 18】 An antibody that specifically binds to the protein having human high-affinity choline transporter activity according to claim 14 or 15.

【Claim 19】 A screening method of a promoter or a suppressor of high-affinity choline transporter activity characterized in evaluating high-affinity choline transporter activity of the protein having high-affinity choline transporter activity according to any one of claims 10 to 15 in the presence of a subject material.

【Claim 20】 A screening method of a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression characterized in comprising the steps of: a cell which can express the protein having high-affinity choline transporter activity according to any one of claims 10 to 15 is cultivated in vitro in the presence of a subject material; the activity and/or the expression amount

of a protein having high-affinity choline transporter activity in the cell is evaluated.

[Claim 21] A screening method of a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression characterized in administering a subject material to a non-human animal and then evaluating the activity and/or the expression amount of a protein having high-affinity choline transporter activity according to any one of claims 10 to 15 in a cell which can express a protein having high-affinity choline transporter activity.

[Claim 22] A preparing method of a cell having high-affinity choline transporter activity characterized in introducing the gene or the DNA according to any one of claims 7 to 9 into a cell whose function of a high-affinity choline transporter gene is deficient on its chromosome.

[Claim 23] The preparing method of a cell having high-affinity choline transporter activity according to claim 22, wherein the cell having high-affinity choline transporter activity is integrated with the gene or the DNA according to any one of claims 7 to 9 in its chromosome, and stably shows high-affinity choline transporter activity.

[Claim 24] A cell having high-affinity choline transporter activity being obtainable by the preparing method of a cell having high-affinity choline transporter activity according to claim 22 or 23.

[Claim 25] A non-human animal whose function of a high-affinity choline transporter gene is deficient or overexpresses on its chromosome.

[Claim 26] The non-human animal according to claim 25, wherein the non-human animal is a mouse or a rat.

[Claim 27] A screening method of a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression characterized in administering a subject material to the non-human animal according to claim 25 or 26.

[Detailed Description of the Invention]

[0001]

[Technical Field to Which the Invention Pertains]

This invention relates to a protein having high-affinity choline transporter activity, a gene encoding said protein and the use of the same.

[0002]

[Prior Art]

The autonomic nervous system which spreads to organs throughout a body and regulates the most basic functions of living organism including energy metabolism, circulation, respiration and reproduction along with endocrine system, is classified into the sympathetic and parasympathetic nervous systems. All autonomic nerve fibers excluding postganglionic fibers of the sympathetic nerve, motor nerve fiber, and sudoriferous gland/blood vessel dilative fiber in the sympathetic nerve are cholinergic, and acetylcholine is vital for the function of the autonomic nerve and the motor nerve. It has been known that the cholinergic neuron, being observed also in the brain, is important for recognizing function of the brain and that it degenerates after the onset of Alzheimer's disease. In the cholinergic neuron, because of lack of biosynthetic ability for choline, choline, an acetylcholine decomposition product, is taken up into a cell by a high-affinity choline transporter at the presynaptic terminals to be reused for synthesizing

acetylcholine. The high-affinity choline uptake is a rate-limiting step for acetylcholine synthesis and is presumed to regulate the efficiency of synaptic transmission (J. Neurochem. 18, 781-798, 1971, Science 178, 626-628, 1972, Biochem. Biophys. Acta 291, 564-575, 1973, Mol. Pharmacol. 9, 630-639, 1973, J. Pharmacol. Exp. Ther. 192, 86-94, 1975, J. Neurochem. 30, 15-21, 1978, J. Neurochem. 44, 11-24, 1985, J. Neurochem. 60, 1191-1201, 1993, J. Neurochem. 20, 581-593, 1973, Eur. J. Pharmacol. 102, 369-370, 1984). To date, most of cDNAs of transporters for major neurotransmitters have been isolated, however, a cDNA of the high-affinity choline transporter, which is physiologically important, has not been identified.

[0003]

[An Object to be Attained]

So far, the existence of a protein being localized in the cholinergic neuron and having a function of taking up choline, a precursor of acetylcholine, into a cell has been expected, but molecular properties of said protein, a high-affinity choline transporter, have been unknown. An object of the present invention is to provide a physiologically important protein having the high-affinity choline transporter activity, a gene which encodes the protein, and a screening method of a high-affinity choline transporter activity promoter using the protein, the gene and the like.

[0004]

[Means to Attain the Object]

The inventors have conducted intensive study to attain the above-mentioned object: with information of genomic project (Science 282, 2012-2018, 1998), Na⁺-dependent transporter cDNAs being expected from the genomic sequence of a nematode (C.

elegans) were cloned one by one, and the high-affinity choline uptake activity of each cDNA was examined in the oocyte expression system of *Xenopus*, and the cDNA of nematode high-affinity choline transporter (cho-1) was identified on the basis of the above examination, then homologous molecules (CHT1) were cloned from rat spinal cord by using the homology of a base sequence to the cDNA as an index. This CHT1 had no homology to neurotransmitter transporters (J. Neurochem. 71, 1785-1803, 1998), but had 20 to 25% homology to molecules which belong to Na⁺-dependent glucose transporter family (Nature 330, 379-381, 1987).

[0005]

Northern blot analysis revealed that transcripts of CHT1 were confirmed only in spinal cord, basal forebrain, corpus striatum and brain stem, and CHT1 seemed to be expressed in cholinergic neurons. Accordingly, CHT1 was expressed in oocytes of *Xenopus*. As a result, choline uptake activity that is Na⁺-dependent and completely inhibited by hemicholinium-3 was observed. These results indicate that CHT1 has high-affinity choline transporter activity. Further, the inventors have cloned choline transporter cDNAs derived from a human, and determined their base sequences, and have confirmed that their expression products have high-affinity choline uptake activity. The present invention has thus completed.

[0006]

The present invention relates to a gene which encodes a protein (a) or (b) described below; (a) a protein comprising an amino acid sequence represented by Seq. ID No. 2, (b) a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No. 2, and having high-affinity choline

transporter activity (claim 1), DNA containing a base sequence represented by Seq. ID No. 1 or its complementary sequence and a part or a whole of these sequences (claim 2), DNA derived from a nematode which hybridizes with DNA according to claim 2 under a stringent condition, and encodes a protein having high-affinity choline transporter activity (claim 3), a gene which encodes a protein (a) or (b) described below; (a) a protein comprising an amino acid sequence represented by Seq. ID No. 4, (b) a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No. 4, and having high-affinity choline transporter activity. (claim 4), DNA containing a base sequence represented by Seq. ID No. 3 or its complementary sequence and a part or a whole of these sequences (claim 5), DNA derived from a rat which hybridizes with DNA comprising a gene according to claim 5 under a stringent condition, and encodes a protein having high-affinity choline transporter activity (claim 6), a gene which encodes a protein (a) or (b) described below; (a) a protein comprising an amino acid sequence represented by Seq. ID No. 6, (b) a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No. 6, and having high-affinity choline transporter activity (claim 7), DNA containing a base sequence represented by Seq. ID No. 5 or its complementary sequence and a part or a whole of these sequences (claim 8), DNA derived from a human which hybridizes with DNA comprising a gene according to claim 8 under a stringent condition, and encodes a protein having high-affinity choline transporter activity (claim 9), a protein comprising an amino acid sequence represented by Seq. ID No. 2 and having nematode high-affinity

choline transporter activity (claim 10), a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.2, and having nematode high-affinity choline transporter activity(claim 11), a protein comprising an amino acid sequence represented by Seq. ID No. 4 and having rat high-affinity choline transporter activity (claim 12), a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.4, and having rat high-affinity choline transporter activity (claim 13), a protein comprising an amino acid sequence represented by Seq. ID No. 6 and having human high-affinity choline transporter activity (claim 14), and a protein comprising an amino acid sequence where one or a few amino acids are deficient, substituted or added in the amino acid sequence represented by Seq. ID No.6, and having human high-affinity choline transporter activity (claim 15).

[0007]

The present invention also relates to an antibody that specifically binds to the protein having nematode high-affinity choline transporter activity according to claim 10 or 11 (claim 16), an antibody that specifically binds to the protein having rat high-affinity choline transporter activity according to claim 12 or 13 (claim 17), and an antibody that specifically binds to the protein having human high-affinity choline transporter activity according to claim 14 or 15 (claim 18).

[0008]

The present invention further relates to a screening method of a promoter or a suppressor of high-affinity choline transporter activity characterized in evaluating high-affinity

choline transporter activity of the protein having high-affinity choline transporter activity according to any one of claims 10 to 15 in the presence of a subject material (claim 19), a screening method of a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression characterized in comprising the steps of: a cell which can express the protein having high-affinity choline transporter activity according to any one of claims 10 to 15 is cultivated in vitro in the presence of a subject material; the activity and/or the expression amount of a protein having high-affinity choline transporter activity in the cell is evaluated (claim 20), a screening method of a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression characterized in administering a subject material to a non-human animal and then evaluating the activity and/or the expression amount of a protein having high-affinity choline transporter activity according to any one of claims 10 to 15 in a cell which can express a protein having high-affinity choline transporter activity (claim 21), a preparing method of a cell having high-affinity choline transporter activity characterized in introducing the gene or the DNA according to any one of claims 7 to 9 into a cell whose function of a high-affinity choline transporter gene is deficient on its chromosome (claim 22), the preparing method of a cell having high-affinity choline transporter activity according to claim 22, wherein the cell having high-affinity choline transporter activity is integrated with the gene or the DNA according to any one of claims 7 to 9 in its chromosome, and stably shows high-affinity choline transporter activity (claim 23), a cell having high-affinity choline transporter activity

being obtainable by the preparing method of a cell having high-affinity choline transporter activity according to claim 22 or 23 (claim 24), a non-human animal whose function of a high-affinity choline transporter gene is deficient or overexpresses on its chromosome (claim 25), the non-human animal according to claim 25, wherein the non-human animal is a mouse or a rat (claim 26), a screening method of a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression characterized in administering a subject material to the non-human animal according to claim 25 or 26 (claim 27).

[0009]

[Mode for Carrying out the Invention]

The cDNA of nematode high-affinity choline transporter of the present invention, being described in Seq. ID No. 1, can be obtained by injecting each cRNA prepared from candidate full-length cDNAs, which are expected as a member of Na^+ -dependent transporter family according to C. elegans genome project, into oocytes of Xenopus, and examining the uptake of choline. The high-affinity uptake of choline in brain synaptosomes of mammals was completely inhibited by 1 μM hemicholinium-3 (HC3) ($K_i=10-100$ nM), while the low-affinity uptake of choline, which is distributed in every cells, was inhibited only by HC3 with higher concentration ($K_i=50$ μM). Therefore, the sensitivity to 1 μM HC3 can be used as criteria of high-affinity choline uptake during the process. For example, it is possible to confirm the identification, the expression, and the localization of an object gene from the candidate cDNA of C. elegans as follows.

[0010]

It has been found that cDNA corresponding to the gene

expected as C48D1.3 promotes significant choline uptake, being inhibited by 1 μ M HC3, in the high-affinity choline uptake process. Fig. 1 shows the result of [3 H] choline uptake of oocytes from *Xenopus* being injected with C48D1.3 cRNA or water. In Fig. 1, the closed and the open columns indicate choline uptake in the absence or the presence of 1 μ M HC3 respectively, and each column is shown by mean \pm SEM (n=6 to 8 oocytes). Fig. 2 shows the effect of Na $^+$ on the choline uptake, and the closed columns indicate choline uptake measured in the standard solution ([Na $^+$]=100 mM), the open columns indicate choline uptake in the absence of Na $^+$ (Na $^+$ was substituted with Li $^+$). In addition, Fig. 3 shows the inhibition of choline uptake induced by HC3. Based on the above-mentioned Fig. 2 and 3, it is presumed that the uptake is Na $^+$ -dependent, and that K $_i$ of HC3 is 50 nM. The cDNA clone was designated as cho-1 (high-affinity choline transporter-1).

[0011]

By comparing a base sequence of cDNA and that of genome, cho-1 gene was found to comprise 9 exons. A protein expected from a base sequence of cDNA of cho-1 includes 576 amino acid residues (see Fig. 4), and this protein, being represented by Seq. ID No. 2, can be constructed by a usual method. When the available data base was searched, the amino acid sequences of cho-1 showed weak, but significant homology to members of Na $^+$ -dependent glucose transporter family. Hydrophobic analysis and comparison to other transporters suggest that there is a twelve-transmembrane region (see Fig. 7).

[0012]

Then, in order to identify cells expressing cho-1 in the nervous system of *C. elegans*, a gene of a green fluorescent protein (GFP) fused with a region 5.1kb upstream from cho-1 gene was

introduced into a nematode, and distribution of neurons expressing cho-1::gfp was examined. A photograph of L1 larva possessing cho-1::gfp reporter DNA at the outside of chromosome is shown as Fig. 5 (scale bar; 50 μ m). In Fig. 5, the arrowhead indicates nervering. In the ventral nerve cord, GFP is expressed only in cholinergic motor nerve, however, some of DA, DB nerve cells do not express GFP owing probably to deficiency of reporter DNA at the outside of chromosome. It supports the idea that cho-1 is a high-affinity choline transporter of the cholinergic neuron.

[0013]

The cDNA of rat high-affinity choline transporter of the present invention, being described in Seq. ID No. 3, can be prepared, for example, by a method comprising the steps of: paying attention to cho-1 homologous molecules of vertebrates and searching data base with amino acid sequences expected from cho-1, and identifying one candidate (GenBank accession number AQ 316435) in human genomic survey sequence (GSS); amplifying cDNA fragments from rat spinal cord cDNA by PCR with degenerate primers on the basis of homology of base sequences between the human genome DNA and cho-1; screening rat spinal cord cDNA library with this fragment, and a positive cDNA clone was obtained. A protein with 580 amino acid residues showing 51% identity and 70% similarity to cho-1 was expected from the base sequence of the longest reading frame (see Fig. 4). This rat cDNA clone was designated as CHT1. In Fig. 4, each amino acid sequence of rat CHT1 and *C. elegans* CHO-1 is shown, and the identical and the similar residues are indicated on a black ground and a gray ground respectively. The expected transmembrane region I-XII is underlined. This protein represented by Seq. ID No.

4 can be constructed by a usual method.

[0014]

The above-mentioned amino acid sequence of CHT1 is significantly homologous to members of Na⁺-dependent glucose transporter family (20 to 25%). The phylogenetic tree of Na⁺-dependent glucose transporter family made by neighbor-joining method using a program CLUSTALW of National Institute of Genetics (Mishima, Japan) is shown in Fig. 6. In Fig. 6, the percentage of the identical amino acids, being contained in each protein, to rat CHT1 is shown on the right side. On the other hand, no homology was observed to a yeast choline transporter (J. Biol. Chem. 265, 15996-16003, 1990), a creatine transporter which had been originally reported as a high-affinity choline transporter (Biochem. Biophys. Res. Commun. 198, 637-645, 1994), and other neurotransmitter transporters.

[0015]

The expected topology of CHT1 is thought to be the same as that of *C. elegans* CHO-1 fundamentally. Fig. 7 shows the expected topology of rat CHT1. In Fig. 7, the closed circles indicate the identical residues, the shadowed circles indicate highly conserved residues, and open circles indicate nonsimilar residues. The offshoots indicate the expected glycosylation sites. P among the circles shows the expected parts of phosphorylation induced by protein kinase C.

[0016]

Next, the distribution of CHT1 mRNA expression was examined by Northern blot analysis and *in situ* hybridization. The expression of transcripts with the length of about 5 kb was confirmed by Northern blot analysis of various tissues of rats.

Fig. 8 shows the result of Northern blot analysis of mRNA transcript of CHT1 in rat tissue, and the length of RNA standard (0.24 to 9.5 kb; GIBCO BRL) is exhibited on the left side. As shown in Fig. 8, an abundance of transcripts were confirmed in basal forebrain, brain stem and spinal cord, and a little of those were confirmed in corpus striatum. These tissues are known to contain cholinergic neurons. On the other hand, no transcript was observed in other regions of the brain or in tissues of non-nervous systems.

[0017]

Consistent with these results, *in situ* hybridization confirmed the expression of CHT1 mRNA in cell groups of main cholinergic neurons including corpus striatum, cell population in basal forebrain and ventral horn in spinal cord. Fig. 9 and 10 (scale bar; 1mm) show micrographs of sections in bright-field, which were hybridized with a cRNA probe of an antisense labeled by digoxigenin. These micrographs relate to *in situ* hybridization analysis of CHT1 transcripts in rat brain and spinal cord. Fig. 9 indicates that mRNA transcripts of CHT1 were detected in vertical and horizontal limbs of the diagonal band (VDB, HDB), medial septal nucleus (MS), caudate and putamen (Cpu), and olfactory tubercle (Tu). Fig. 10 indicates that the expression was observed in ventral horn (VH) in spinal cord. Further, the adjacent section hybridized with a probe of vesicle acetylcholine transporter showed essentially same distribution. This expression distribution is essentially same as the reported distribution of choline acetyl group transferase or vesicle acetylcholine transporter. These results show that the expression of CHT1 mRNA is limited to cholinergic neurons.

[0018]

Next, choline uptake of CHT1 was examined by using oocytes of *Xenopus*. The choline uptake of the oocytes injected with CHT1 cRNA was 2 times to 4 times more than that of controls injected with water. Fig. 11 shows the result of [^3H] choline uptake of oocytes of *Xenopus* injected with CHT1 cRNA or water. In Fig. 11, the open and the closed columns respectively indicate choline uptake in the standard solutions containing 100 mM NaCl or LiCl, and each column is shown by mean \pm SEM (n=6 to 8 oocytes). The effect of choline concentration on choline uptake is shown in Fig. 12. In Fig. 12, choline uptake of oocytes injected with water was subtracted from that of oocytes injected with cRNA in order to figure out CHT1-induced choline uptake, and the choline uptake was fitted to Michaelis-Menten curve. As shown in Fig. 12, choline uptake of CHT1 saturated when increasing choline concentration ($K_m=2.2 \pm 0.2 \mu\text{M}$, n=3).

[0019]

Then, the result of HC3-induced inhibition of choline uptake is shown in Fig. 13. Fig. 13 indicates that the K_m of endogenous choline uptake of control is higher than 10 μM and that choline uptake of CHT1 is completely inhibited by 0.1 μM HC3 ($K_i=2-3 \text{ nM}$), whereas 10 μM HC3 induced only slight inhibition in control. As shown in Fig. 14, ion-dependency of choline uptake of CHT1 was examined and found to be Cl^- -dependent as well as Na^+ -dependent. The closed and the open columns indicate choline uptake of oocytes injected with water and with cRNA respectively (100 mM NaCl in the standard solution is substituted with 100 mM of each salt) shown in the figure. These results indicate that CHT1 has the characteristics expected from high-affinity choline uptake in brain synaptosomes (high-affinity to choline, high sensitivity to HC3, and Na^+ - Cl^- -dependency) (J. Neurochem.

27, 93-99, 1976).

[0020]

In addition, [^3H] HC3 binding activity of membranes prepared from COS7 cells introduced with CHT1 cDNA and a vector (control) respectively was examined. The result is shown in Fig. 15. As Fig. 15 indicates, Na^+ -dependent [^3H] HC3 binding was observed in a membrane of a cell where CHT1 was expressed, but not in a control membrane. Subsequently, a saturation analysis was conducted for specific [^3H] HC3 binding. As shown in Fig. 16, equilibrium dissociation constant (K_d) was estimated to be $1.6 \pm 0.2 \mu\text{M}$ ($n=3$). This value was similar to that reported in brain synaptosomes (J. Neurochem. 60, 1191-1201, 1993, Life Sci. 35, 2335-2343, 1984, Brain Res. 348, 321-330, 1985). Further, displacement of specific [^3H] HC3 binding by HC3, choline (Cho) and acetylcholine (Ach) was examined. Acetylcholine was measured in the presence of $1 \mu\text{M}$ physostigmine. The result is shown in Fig. 17. Fig. 17 indicates that specific [^3H] HC3 binding was displaced when the concentration of choline was at least about 10 times lower than that of acetylcholine. These results show that CHT1 is a HC3 binding site as well as a high-affinity choline transporter.

[0021]

The cDNA of human high-affinity choline transporter of the present invention, being represented by Seq. ID No.5, can be prepared, for example, as follows: data base search was conducted with the amino acid sequence of nematode (*C. elegans*) CHO-1 to find a sequence of specific human genome DNA fragment having significant homology (R-107P12, a clone of human genomic survey sequence; GenBank accession number: AQ316435); a gene-specific primers for PCR were designed based on a base

sequence of said DNA fragment; 5'-RACE (rapid amplification of cDNA ends) and 3'-RACE were conducted using Marathon-Ready™ cDNA (Clontech) of human whole brain, together with an attached adapter primer; the obtained PCR product was cloned into a cloning vector for PCR, and a base sequence of inserted DNA was determined. In addition, an amino acid sequence expected from this DNA sequence is represented by Seq. ID No. 6. A protein having human high-affinity choline transporter activity represented by said Seq. ID No. 6 can be constructed by a usual method on the basis of DNA sequence information shown in Seq. ID No. 5.

[0022]

As examples of a protein having high-affinity choline transporter activity of the present invention, in addition to the ones represented by Seq. ID Nos. 2, 4, and 6, which are specifically disclosed above, a protein comprising an amino acid sequence wherein one or a few amino acids are deficient, substituted or added in amino acid sequences represented by Seq. ID Nos. 2, 4, and 6, and having high-affinity choline transporter activity is also included. These proteins can be prepared by known methods. Further, examples of a gene or DNA encoding a protein having high-affinity choline transporter activity of the present invention include, in addition to the ones represented by Seq. ID Nos. 1, 3, and 5, which are specifically disclosed above, a gene or DNA which encodes a protein comprising an amino acid sequence wherein one or a few amino acids are deficient, substituted or added in amino acid sequences represented by Seq. ID Nos. 2, 4, and 6, and having high-affinity choline transporter activity, and DNA which encodes a protein hybridizing with said gene or DNA under a stringent condition and having high-affinity choline transporter activity. These

genes and DNAs can be prepared by known methods.

[0023]

Cholinergic neurons play an extremely important role in learning and memory. The damage of these neurons correlates to severity of dementia. The rate-limiting step in acetylcholine synthesis is presumed to be the uptake of choline, and its activity is controlled by neural activity or various kinds of stimuli. In the brains of patients who suffer Alzheimer's disease, the hyperfunction of high-affinity choline uptake and of HC3 binding activity are observed (Trends Neurosci. 15, 117-122, 1992, Ann. NY Acad. Sci. 777, 197-204, 1996, J. Neurochem. 69, 2441-2451, 1997). Cloning of said gene or DNA encoding a protein having high-affinity choline transporter activity and said protein having high-affinity choline transporter activity is important for elucidating the molecular mechanism of the high-affinity choline transporter and for developing new therapies for Alzheimer's disease.

[0024]

An antibody that specifically combines with a protein having high-affinity choline transporter activity of the present invention can be constructed by a usual method with the above-mentioned protein having high-affinity choline transporter activity as an antigen, and a monoclonal antibody is preferable because of its specificity. Said monoclonal antibody is useful, for instance, for elucidating molecular mechanism of regulation of a high-affinity choline transporter.

[0025]

By using the gene or DNA that encodes a protein having high-affinity choline transporter activity, or a protein having high-affinity choline transporter activity, it becomes possible

to screen a pharmaceutical material useful for the treatment of Alzheimer's disease, in other words, a material that promotes or suppresses the activity or the expression of a high-affinity choline transporter. The screening method of the present invention include a method wherein high-affinity choline transporter activity of a protein having high-affinity choline transporter activity of the present invention is evaluated in the presence of a subject material, a method wherein a cell which can express a protein having high-affinity choline transporter activity of the present invention is cultivated in vitro in the presence of a subject material, and the activity and/or the expression amount of a protein having high-affinity choline transporter activity in the cell is evaluated, and a method wherein a subject material is administered to a non-human animal and then the activity and/or the expression amount of a protein having high-affinity choline transporter activity in a cell which can express a protein having high-affinity choline transporter activity of the present invention is evaluated.

[0026]

In addition, cells being useful for gene therapy of Alzheimer's disease and the like can be prepared by using a whole or a part of a gene or DNA that encodes a protein having high-affinity choline transporter activity of the present invention. As an example of a method for preparing these cells of the present invention, a method wherein a whole or a part of said gene or DNA of the present invention is introduced into a cell being deficient in the function of a high-affinity choline transporter gene on its chromosome by transfection or the like to obtain a cell having high-affinity choline transporter activity is exemplified. As the cell having high-affinity

choline transporter activity, in particular, it is preferable to use a cell wherein said gene or DNA is integrated into a chromosome and high-affinity choline transporter activity is exhibited stably.

[0027]

In the present invention, said non-human animal whose function of a high-affinity transporter gene is deficient on its chromosome means a non-human animal wherein a part or a whole of a high-affinity choline transporter gene on chromosome is inactivated by gene mutation such as disruption, deficiency, substitution, etc. and function of expressing a high-affinity transporter is lost. In addition, a non-human animal that abnormally expresses function of a high-affinity transporter gene on its chromosome means a non-human animal that produces larger amount of a protein having high-affinity transporter activity than a wild-type non-human animal does. Though specific examples of a non-human animal of the present invention include rodents, such as mice, rats and the like, a non-human animal of the present invention is not limited to these animals.

[0028]

In the present invention, wild-type non-human animal means an animal of the same species of said non-human animals whose function of a high-affinity transporter gene is deficient on its chromosome, and a littermate is preferable. Homozygous mice generated according to Mendelian ratio include a deficient type for a high-affinity choline transporter and their littermate wild-type, and it is possible to carry out precise comparative experiments in individual level by using the deficient types and the littermate wild-types of these homozygous mice at the same time. The generating method of the non-human animals being

deficient in the function of a high-affinity transporter gene on their chromosome will be explained below, with an example of knockout mice being deficient in a high-affinity transporter.

[0029]

For example, a mouse being deficient in the function of a high-affinity transporter gene on its chromosome, in other words, a knockout mouse of a high-affinity transporter can be constructed as follows. A high-affinity transporter gene is screened by using a gene fragment obtained from mouse gene library by a method like PCR. The screened high-affinity transporter gene is subcloned with a viral vector or the like, and specified by DNA sequencing. A target vector is constructed by substituting a whole or a part of a high-affinity transporter gene of this clone with pMC1 neo gene cassette or the like, and by introducing a diphtheria toxin A fragment (DT-A) gene, a herpes simplex virus thymidine kinase (HSV-tk) gene or other such genes into 3'-terminal side.

[0030]

This constructed target vector is linearized and introduced into ES cells by electroporation or the like to induce homologous recombination. The ES cells wherein homologous recombination is induced by an antibiotic such as G418, ganciclovir (GANC) or the like are selected from the homologous recombinants. It is preferable to confirm whether the selected ES cells are the recombinants of the object by Southern blot or the like. A chimeric mouse is constructed by microinjecting a clone of the confirmed ES cells into a blastocyst of a mouse and then transplanting the blastocyst into a recipient mouse. A heterozygous mouse can be obtained by intercrossing the chimeric mouse with a wild-type mouse, and a knockout mouse of

a high-affinity transporter of the present invention can be constructed by intercrossing the heterozygous mice. It is possible to confirm whether a knockout mouse of a high-affinity transporter is constructed, for example, by isolating RNA from the mouse obtained by said method and examining it by Northern blot analysis or the like, or by examining the expression of the mouse by Western blot analysis or the like.

[0031]

Further, a promoter or a suppressor of high-affinity choline transporter activity, or of high-affinity choline transporter expression can be screened by administering a subject material to said knockout mouse of a high-affinity transporter and then evaluating the high-affinity transporter activity or the like in the knockout mouse.

[0032]

Experimental methods or the like of the above-mentioned various experiments will now be explained in more detail below.
(Cloning of transporter cDNA)

The candidate cDNA of nematode choline transporter was isolated from poly (A)+RNA of nematode mixture from various stages in the development by reverse transcription PCR and 3' RACE. MarathonTM cDNA Amplification Kit (Clontech) was used according to its protocol. A primer for sense direction of PCR was designed at a provisional translation initiating point of a predicted gene based on a DNA base sequence obtained from C. elegans genomic project. The amplified PCR product was subcloned into Nco I (smoothing) site and Not I site of a modified pSPUTK vector (Stratagene), and the base sequence of inserted DNA was determined. CHT1 cDNA of rat was isolated from rat spinal cord cDNA library by using GeneTrapper cDNA Positive Selection

System (GIBCO Bio-Rad Laboratory: GIBCO BRL) according to its protocol. The primer used was designed from the base sequence of a cDNA fragment obtained by degenerated PCR. The obtained cDNA clones were analyzed. Among them, positive clones were selected and subcloned into pSPUTK vector and pcDNA3.1+ vector (Invitrogen Corporation).

[0033]

(Expression in oocytes of *Xenopus*)

In the presence of cap analog, cRNA was synthesized in vitro with SP6 or T7 RNA polymerase. 20 to 30 ng capped RNA was microinjected into oocytes (stage V to VI) of *Xenopus*. The uptake was measured in basically same manner as described previously (Nature 360, 467-471, 1992). Two or three days after the injection of RNA, choline uptake was conducted for 30 to 60 min. with oocytes (6 to 8) in 0.75 ml standard solution (0.01 to 1 μ M [3 H]-choline, 100 mM NaCl, 2mM KCl, 1mM MgCl₂, 1mM CaCl₂, 10mM HEPES, 5mM Tris: pH 7.4). The oocytes completing uptake were solubilized with 10% SDS, and the amount of [3 H] was measured by a liquid scintillation counter.

[0034]

(GFC expression construct)

The transcriptional fusion construct of cho-1::gfp was constructed by PCR in same manner as described previously (Gene 212, 127-135, 1998). A gene that encodes a green fluorescent protein (GFP) located on downstream of a nuclear localization signal sequence (NLS) was inserted into a position 3 residues downstream of cho-1 translation initiating point so that the reading frame was fitted. NLS and gfp gene were amplified from pPD104.53 vector. In order to prepare 5.1 kb upstream region of cho-1 translation initiating point, a PCR primer being

designed to encompass the first 3 amino acid residues of cho-1 was used. By the same method as previously described (EMBO J. 10, 3959-3970, 1991), rol-6 (sul006) marker and generated DNA were injected into gonads of a nematode simultaneously.

[0035]

(Northern blot analysis)

6 µg poly(A)+RNA prepared from various tissues of rats was separated by formaldehyde-agarose electrophoresis, and transferred to a nylon membrane, then hybridized with CHT1 cDNA fragment being labeled with [³²P] by random prime method in hybridization solution (solution containing the final concentration of 50% formamido, 5 × SSPE, 5 × Denhardt's solution, 0.5% SDS, 100 µg/ml salmon sperm DNA) at 42° C for 16 hours. The nylon membrane was washed under final condition (0.1 × SSPE, 0.1% SDS: 65° C), and then autoradiography was conducted for 7 days together with an enhancing screen.

[0036]

(In situ hybridization)

The transcript of an antisense labeled with digoxigenin was synthesized in vitro. Alkaline hydrolysis was repeated for the transcripts until their mean length was prepared to be 200 to 400 b. Cryostat sections of fresh frozen tissue (10 to 20 µm) were used. Hybridization was conducted with labeled cRNA probe (about 1 µg/ml) dissolved in 1 × Denhardt's solution [solution containing the final concentration of 50 mM Tris-HCl (pH 8.0), 2.5 mM EDTA, 0.3 M NaCl, 50% formamido, 10% dextran sulphate, 1 mg/ml E. coli tRNA] at 45° C for 20 hours. Then the sections were washed twice in 2 × SSC/50% formamido and once in 1 × SSC/50% formamido, at 45° C respectively. The hybridized probe was visualized by using anti-digoxigenin Fab fragment

(Boehringer-Mannheim) and NBT/BCIP substrate. The sections were brought into reaction in substrate solution for 24 to 48 hours.

[0037]

(Binding assay)

[³H] hemicholinium-3 (HC3; 128Ci/mmol) was obtained from NEN Life Science Products. Either pcDNA3.1-CHT1 or pcDNA3.1 was transiently expressed in COS7 cells respectively. TransFast Reagent (Promega) was introduced and used according to the protocol. Membranes were prepared by following steps: homogenizing cells in 0.32 M sucrose; centrifuging the cells for 1 hour at 200,000g; and suspending the precipitate. Binding assay was conducted in basically same manner as described previously. Specific binding amount was calculated by subtracting non-specific binding amount determined in the presence of 10 μ M HC3 from the whole binding amount. The K_d value was figured out by analyzing specific [³H] HC3 binding amount from data of saturation binding assay with nonlinear approximation.

[0038]

(Effect of the Invention)

The present invention makes it possible to provide a protein having high-affinity choline transporter activity, which is physiologically important, and gene DNA encoding said protein. In addition, by using the said protein and gene DNA, it becomes possible to screen materials being useful for prevention or treatment of Alzheimer's disease, and to prepare cells being useful for gene therapy.

[0039]

(Sequence Listing)

SEQUENCE LISTING

<110> Japan Science and Technology Corporation

<120> High-affinity choline transporter

<130> A011P12

<140>

<141>

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 1731

<212> DNA

<213> Caenorhabditis elegans

<220>

<221> CDS

<222> (1)..(1731)

<223> choline transporter from C. elegans

<400> 1

atg gcc gac tta ttg ggt atc gtg gcc att gtg ttc ttc tac gtg ctc 48

Met Ala Asp Leu Leu Gly Ile Val Ala Ile Val Phe Phe Tyr Val Leu

1

5

10

15

att ctt gtc gtt gga ata tgg gcg ggt aga aaa tcg aaa agt tca aaa	96
Ile Leu Val Val Gly Ile Trp Ala Gly Arg Lys Ser Lys Ser Ser Lys	
20 25 30	
gag ctt gaa tca gaa gcc ggc gcg gcg acg gaa gag gtg atg tta gct	144
Glu Leu Glu Ser Glu Ala Gly Ala Ala Thr Glu Glu Val Met Leu Ala	
35 40 45	
ggg aga aac atc gga act ctt gtc gga att ttc aca atg act gcc acg	192
Gly Arg Asn Ile Gly Thr Leu Val Gly Ile Phe Thr Met Thr Ala Thr	
50 55 60	
tgg gtt ggc ggt gct tat atc aat gga acc gcc gag gct ctg tat aat	240
Trp Val Gly Gly Ala Tyr Ile Asn Gly Thr Ala Glu Ala Leu Tyr Asn	
65 70 75 80	
gga ggt ctc ctt gga tgt cag gct cca gtt gga tat gca att tcc ctt	288
Gly Gly Leu Leu Gly Cys Gln Ala Pro Val Gly Tyr Ala Ile Ser Leu	
85 90 95	
gtt atg gga gga cta ctt ttc gca aag aaa atg cga gaa gaa gga tat	336
Val Met Gly Gly Leu Leu Phe Ala Lys Lys Met Arg Glu Glu Gly Tyr	
100 105 110	
att aca atg ctc gat cct ttt cag cac aaa tat ggc caa cga atc ggt	384
Ile Thr Met Leu Asp Pro Phe Gln His Lys Tyr Gly Gln Arg Ile Gly	
115 120 125	
ggc ttg atg tat gtt cca gca ctt ctt ggt gaa aca ttc tgg aca gca	432
Gly Leu Met Tyr Val Pro Ala Leu Leu Gly Glu Thr Phe Trp Thr Ala	

130	135	140	
gcc att ctt tcg gca ctt ggt gca aca ctg tcg gta att ctt gga atc 480			
Ala Ile Leu Ser Ala Leu Gly Ala Thr Leu Ser Val Ile Leu Gly Ile			
145	150	155	160
gac atg aat gca tca gtg acc ctg tcg gcc tgt att gcc gta ttc tac 528			
Asp Met Asn Ala Ser Val Thr Leu Ser Ala Cys Ile Ala Val Phe Tyr			
	165	170	175
aca ttc acc ggt gga tac tat gca gtc gcg tac act gac gtc gtt caa 576			
Thr Phe Thr Gly Gly Tyr Tyr Ala Val Ala Tyr Thr Asp Val Val Gln			
	180	185	190
cta ttt tgc att ttc gtc ggt ttg tgg gtt tgc gtg ccg gcg gct atg 624			
Leu Phe Cys Ile Phe Val Gly Leu Trp Val Cys Val Pro Ala Ala Met			
	195	200	205
gtg cat gat ggt gcg aag gat att tcc agg aat gca ggc gac tgg att 672			
Val His Asp Gly Ala Lys Asp Ile Ser Arg Asn Ala Gly Asp Trp Ile			
	210	215	220
gga gag att gga gga ttc aaa gaa aca tct ctc tgg att gat tgc atg 720			
Gly Glu Ile Gly Gly Phe Lys Glu Thr Ser Leu Trp Ile Asp Cys Met			
225	230	235	240
ctt ctc ctt gtc ttt gga gga att cca tgg caa gtg tac ttc caa aga 768			
Leu Leu Leu Val Phe Gly Gly Ile Pro Trp Gln Val Tyr Phe Gln Arg			
	245	250	255

gtt ctc tcc tca aaa act gct cat gga gca cag acg ttg tgc ttt gtg 816

Val Leu Ser Ser Lys Thr Ala His Gly Ala Gln Thr Leu Ser Phe Val

260

265

270

gcg ggc gtc gga tgc att ctc atg gcg att cca cca gcg ttg atc ggt 864

Ala Gly Val Gly Cys Ile Leu Met Ala Ile Pro Pro Ala Leu Ile Gly

275

280

285

gca att gcc agg aac aca gac tgg aga atg act gat tat tcc cca tgg 912

Ala Ile Ala Arg Asn Thr Asp Trp Arg Met Thr Asp Tyr Ser Pro Trp

290

295

300

aac aat gga act aag gtc gaa tcg att cca ccg gat aag aga aac atg 960

Asn Asn Gly Thr Lys Val Glu Ser Ile Pro Pro Asp Lys Arg Asn Met

305

310

315

320

gtg gtc ccg ttg gta ttc cag tat ctt acg cca aga tgg gtc gcc ttt 1008

Val Val Pro Leu Val Phe Gln Tyr Leu Thr Pro Arg Trp Val Ala Phe

325

330

335

att gga ctc ggc gca gtg tgc gct gct gta atg tca tct gca gat tca 1056

Ile Gly Leu Gly Ala Val Ser Ala Ala Val Met Ser Ser Ala Asp Ser

340

345

350

tct gta cta tca gca gca tca atg ttt gct cac aac atc tgg aag ctc 1104

Ser Val Leu Ser Ala Ala Ser Met Phe Ala His Asn Ile Trp Lys Leu

355

360

365

aca att cgc cct cac gcg tct gaa aaa gaa gtg ata att gtg atg aga 1152

Thr Ile Arg Pro His Ala Ser Glu Lys Glu Val Ile Ile Val Met Arg

370	375	380	
ata gcc atc atc tgt gtt ggt atc atg gca acc atc atg gca ctt acc 1200			
Ile Ala Ile Ile Cys Val Gly Ile Met Ala Thr Ile Met Ala Leu Thr			
385	390	395	400
att caa tcc atc tat ggg ctt tgg tat ctt tgt gca gat ttg gtc tac 1248			
Ile Gln Ser Ile Tyr Gly Leu Trp Tyr Leu Cys Ala Asp Leu Val Tyr			
	405	410	415
gtc ata ctc ttc cct caa cta tta tgt gtt gta tat atg cca cgt agc 1296			
Val Ile Leu Phe Pro Gln Leu Leu Cys Val Val Tyr Met Pro Arg Ser			
	420	425	430
aat acg tat ggc tca ttg gct ggc tat gca gtc ggt ctt gtg ctc cgt 1344			
Asn Thr Tyr Gly Ser Leu Ala Gly Tyr Ala Val Gly Leu Val Leu Arg			
	435	440	445
ttg att gga ggc gag cca ctt gta tgc ctg cca gcg ttc ttc cat tat 1392			
Leu Ile Gly Gly Glu Pro Leu Val Ser Leu Pro Ala Phe Phe His Tyr			
450	455	460	
cca atg tat acg gat ggg gta cag tat ttc cca ttc agg aca act gct 1440			
Pro Met Tyr Thr Asp Gly Val Gln Tyr Phe Pro Phe Arg Thr Thr Ala			
465	470	475	480
atg tta tct tca atg gct act atc tac att gta tca ata caa tgc gag 1488			
Met Leu Ser Ser Met Ala Thr Ile Tyr Ile Val Ser Ile Gln Ser Glu			
	485	490	495

aag ctg ttc aaa tcg gga cgt ttg tct ccg gag tgg gac gta atg ggt 1536
 Lys Leu Phe Lys Ser Gly Arg Leu Ser Pro Glu Trp Asp Val Met Gly

500 505 510

tgt gta gtg aat att ccg ata gat cat gta ccc ctt ccg tca gat gta 1584
 Cys Val Val Asn Ile Pro Ile Asp His Val Pro Leu Pro Ser Asp Val

515 520 525

tcg ttt gct gtt agt agt gag acc ttg aat atg aag gct cca aac gga 1632
 Ser Phe Ala Val Ser Ser Glu Thr Leu Asn Met Lys Ala Pro Asn Gly

530 535 540

aca ccg gct cca gta cat ccg aac caa cag ccg tct gat gaa aat aca 1680
 Thr Pro Ala Pro Val His Pro Asn Gln Gln Pro Ser Asp Glu Asn Thr

545 550 555 560

tta tta cat cca tat tcg gac caa agt tat tat tcc aca aat agc aat 1728
 Leu Leu His Pro Tyr Ser Asp Gln Ser Tyr Tyr Ser Thr Asn Ser Asn

565 570 575

taa 1731

<210> 2

<211> 576

<212> PRT

<213> Caenorhabditis elegans

<400> 2

Met Ala Asp Leu Leu Gly Ile Val Ala Ile Val Phe Phe Tyr Val Leu
1 5 10 15

Ile Leu Val Val Gly Ile Trp Ala Gly Arg Lys Ser Lys Ser Ser Lys
20 25 30

Glu Leu Glu Ser Glu Ala Gly Ala Ala Thr Glu Glu Val Met Leu Ala
35 40 45

Gly Arg Asn Ile Gly Thr Leu Val Gly Ile Phe Thr Met Thr Ala Thr
50 55 60

Trp Val Gly Gly Ala Tyr Ile Asn Gly Thr Ala Glu Ala Leu Tyr Asn
65 70 75 80

Gly Gly Leu Leu Gly Cys Gln Ala Pro Val Gly Tyr Ala Ile Ser Leu
85 90 95

Val Met Gly Gly Leu Leu Phe Ala Lys Lys Met Arg Glu Glu Gly Tyr
100 105 110

Ile Thr Met Leu Asp Pro Phe Gln His Lys Tyr Gly Gln Arg Ile Gly
115 120 125

Gly Leu Met Tyr Val Pro Ala Leu Leu Gly Glu Thr Phe Trp Thr Ala
130 135 140

Ala Ile Leu Ser Ala Leu Gly Ala Thr Leu Ser Val Ile Leu Gly Ile
145 150 155 160

Asp Met Asn Ala Ser Val Thr Leu Ser Ala Cys Ile Ala Val Phe Tyr

165

170

175

Thr Phe Thr Gly Gly Tyr Tyr Ala Val Ala Tyr Thr Asp Val Val Gln

180

185

190

Leu Phe Cys Ile Phe Val Gly Leu Trp Val Cys Val Pro Ala Ala Met

195

200

205

Val His Asp Gly Ala Lys Asp Ile Ser Arg Asn Ala Gly Asp Trp Ile

210

215

220

Gly Glu Ile Gly Gly Phe Lys Glu Thr Ser Leu Trp Ile Asp Cys Met

225

230

235

240

Leu Leu Leu Val Phe Gly Gly Ile Pro Trp Gln Val Tyr Phe Gln Arg

245

250

255

Val Leu Ser Ser Lys Thr Ala His Gly Ala Gln Thr Leu Ser Phe Val

260

265

270

Ala Gly Val Gly Cys Ile Leu Met Ala Ile Pro Pro Ala Leu Ile Gly

275

280

285

Ala Ile Ala Arg Asn Thr Asp Trp Arg Met Thr Asp Tyr Ser Pro Trp

290

295

300

Asn Asn Gly Thr Lys Val Glu Ser Ile Pro Pro Asp Lys Arg Asn Met

305

310

315

320

Val Val Pro Leu Val Phe Gln Tyr Leu Thr Pro Arg Trp Val Ala Phe
325 330 335

Ile Gly Leu Gly Ala Val Ser Ala Ala Val Met Ser Ser Ala Asp Ser
340 345 350

Ser Val Leu Ser Ala Ala Ser Met Phe Ala His Asn Ile Trp Lys Leu
355 360 365

Thr Ile Arg Pro His Ala Ser Glu Lys Glu Val Ile Ile Val Met Arg
370 375 380

Ile Ala Ile Ile Cys Val Gly Ile Met Ala Thr Ile Met Ala Leu Thr
385 390 395 400

Ile Gln Ser Ile Tyr Gly Leu Trp Tyr Leu Cys Ala Asp Leu Val Tyr
405 410 415

Val Ile Leu Phe Pro Gln Leu Leu Cys Val Val Tyr Met Pro Arg Ser
420 425 430

Asn Thr Tyr Gly Ser Leu Ala Gly Tyr Ala Val Gly Leu Val Leu Arg
435 440 445

Leu Ile Gly Gly Glu Pro Leu Val Ser Leu Pro Ala Phe Phe His Tyr
450 455 460

Pro Met Tyr Thr Asp Gly Val Gln Tyr Phe Pro Phe Arg Thr Thr Ala
465 470 475 480

Met Leu Ser Ser Met Ala Thr Ile Tyr Ile Val Ser Ile Gln Ser Glu
485 490 495

Lys Leu Phe Lys Ser Gly Arg Leu Ser Pro Glu Trp Asp Val Met Gly
500 505 510

Cys Val Val Asn Ile Pro Ile Asp His Val Pro Leu Pro Ser Asp Val
515 520 525

Ser Phe Ala Val Ser Ser Glu Thr Leu Asn Met Lys Ala Pro Asn Gly
530 535 540

Thr Pro Ala Pro Val His Pro Asn Gln Gln Pro Ser Asp Glu Asn Thr
545 550 555 560

Leu Leu His Pro Tyr Ser Asp Gln Ser Tyr Tyr Ser Thr Asn Ser Asn
565 570 575

<210> 3

<211> 1743

<212> DNA

<213> rat

<220>

<221> CDS

<222> (1)..(1743)

<223> choline transporter from rat

<400> 3

alg cct ttc cat gta gaa gga cta gla gcg att atc ctg ttc tac ctt	48
Met Pro Phe His Val Glu Gly Leu Val Ala Ile Ile Leu Phe Tyr Leu	
1 5 10 15	
ctt ata ttt ctg gtt gga ata tgg gct gca tgg aaa acc aaa aac agc	96
Leu Ile Phe Leu Val Gly Ile Trp Ala Ala Trp Lys Thr Lys Asn Ser	
20 25 30	
ggt aat gca gaa gaa cgc agc gaa gcc atc ata gtt ggg ggc cga gac	144
Gly Asn Ala Glu Glu Arg Ser Glu Ala Ile Ile Val Gly Gly Arg Asp	
35 40 45	
att ggt ttg ttg gtt ggt ggt ttt acc atg aca gcc acc tgg gtt gga	192
Ile Gly Leu Leu Val Gly Gly Phe Thr Met Thr Ala Thr Trp Val Gly	
50 55 60	
gga ggt tac atc aac ggg aca gct gaa gca gtt tat ggg cca ggt tgt	240
Gly Gly Tyr Ile Asn Gly Thr Ala Glu Ala Val Tyr Gly Pro Gly Cys	
65 70 75 80	
ggt cta gct tgg gct cag gca ccc att gga tat tct ctg agt ctg att	288
Gly Leu Ala Trp Ala Gln Ala Pro Ile Gly Tyr Ser Leu Ser Leu Ile	
85 90 95	
tta ggt ggc ctg ttt ttt gca aaa cct atg cgt tcc aag gga tat gtg	336
Leu Gly Gly Leu Phe Phe Ala Lys Pro Met Arg Ser Lys Gly Tyr Val	
100 105 110	
act atg tta gac ccg ttt caa cag atc tat gga aag cgc atg ggt ggg	384
Thr Met Leu Asp Pro Phe Gln Gln Ile Tyr Gly Lys Arg Met Gly Gly	

115	120	125	
ctg ctg ttc atc cct gca ctg atg gga gag atg ttc tgg gct gca gca	432		
Leu Leu Phe Ile Pro Ala Leu Met Gly Glu Met Phe Trp Ala Ala Ala			
130	135	140	
att ttc tct gca tta ggg gct acc atc agc gta atc att gat gtg gat	480		
Ile Phe Ser Ala Leu Gly Ala Thr Ile Ser Val Ile Ile Asp Val Asp			
145	150	155	160
gtg aac ata tcg gtc att gtc tcc gca ctc att gcc att ctt tat acc	528		
Val Asn Ile Ser Val Ile Val Ser Ala Leu Ile Ala Ile Leu Tyr Thr			
165	170	175	
ctc gtg gga ggg ctc tac tct gtg gca tat act gat gtt gta cag cta	576		
Leu Val Gly Gly Leu Tyr Ser Val Ala Tyr Thr Asp Val Val Gln Leu			
180	185	190	
ttc tgc att ttt ata gga ttg tgg atc agt gtc cca ttt gcc ctg tca	624		
Phe Cys Ile Phe Ile Gly Leu Trp Ile Ser Val Pro Phe Ala Leu Ser			
195	200	205	
cat cct gta gtc acc gac att gga ttc act gct gtg cat gct aaa tac	672		
His Pro Val Val Thr Asp Ile Gly Phe Thr Ala Val His Ala Lys Tyr			
210	215	220	
cag agt ccc tgg ctg gga acc att gaa tca gtt gaa gtc tac acc tgg	720		
Gln Ser Pro Trp Leu Gly Thr Ile Glu Ser Val Glu Val Tyr Thr Trp			
225	230	235	240

ctt gat aat ttt ctg ttg ttg atg ctg ggt gga ata cca tgg caa gcc 768

Leu Asp Asn Phe Leu Leu Leu Met Leu Gly Gly Ile Pro Trp Gln Ala

245

250

255

tac ttc cag agg gtc ctc tct tca tcg tca gcg acc tat gct cag gtg 816

Tyr Phe Gln Arg Val Leu Ser Ser Ser Ser Ala Thr Tyr Ala Gln Val

260

265

270

ctg tcc ttc ctg gca gct ttt ggg tgc ctg gtg atg gct cta cca gcc 864

Leu Ser Phe Leu Ala Ala Phe Gly Cys Leu Val Met Ala Leu Pro Ala

275

280

285

att tgc att ggg gcc att gga gcc tcc aca gac tgg aac caa act gca 912

Ile Cys Ile Gly Ala Ile Gly Ala Ser Thr Asp Trp Asn Gln Thr Ala

290

295

300

tat ggg ttt cca gat ccc aag acc aag gag gaa gca gac atg att ctc 960

Tyr Gly Phe Pro Asp Pro Lys Thr Lys Glu Glu Ala Asp Met Ile Leu

305

310

315

320

ccg att gtt cta cag tac ctc tgc cct gtg tac att tcc ttc ttt ggg 1008

Pro Ile Val Leu Gln Tyr Leu Cys Pro Val Tyr Ile Ser Phe Phe Gly

325

330

335

ctt ggt gct gtt tct gct gct gtc atg tcc tcg gct gac tca tcc atc 1056

Leu Gly Ala Val Ser Ala Ala Val Met Ser Ser Ala Asp Ser Ser Ile

340

345

350

cta tca gca agt tcc atg ttt gct cgg aat atc tac cag ctt tcc ttc 1104

Leu Ser Ala Ser Ser Met Phe Ala Arg Asn Ile Tyr Gln Leu Ser Phe

355	360	365	
aga caa aat gca tca gac aag gaa att gtg tgg gtc atg agg atc act	1152		
Arg Gln Asn Ala Ser Asp Lys Glu Ile Val Trp Val Met Arg Ile Thr			
370	375	380	
gtg ttt gtg ttt gga gca tct gca aca gcc atg gcc ttg ctc acg aag	1200		
Val Phe Val Phe Gly Ala Ser Ala Thr Ala Met Ala Leu Leu Thr Lys			
385	390	395	400
act gtg tat ggg ctc tgg tac ctg agc tct gac ctt gtc tac atc atc	1248		
Thr Val Tyr Gly Leu Trp Tyr Leu Ser Ser Asp Leu Val Tyr Ile Ile			
405	410	415	
atc ttc cca cag ctg ctc tgt gta ctc ttc atc aaa gga acc aac act	1296		
Ile Phe Pro Gln Leu Leu Cys Val Leu Phe Ile Lys Gly Thr Asn Thr			
420	425	430	
tat ggg gca gtt gct ggt tat att ttt gga ctt ttc ctg aga att acc	1344		
Tyr Gly Ala Val Ala Gly Tyr Ile Phe Gly Leu Phe Leu Arg Ile Thr			
435	440	445	
gga gga gag cca tat cta tac ttg cag ccc tta atc ttc tac cct ggt	1392		
Gly Gly Glu Pro Tyr Leu Tyr Leu Gln Pro Leu Ile Phe Tyr Pro Gly			
450	455	460	
tat tac cct gac aag aat ggt ata tac aat cag agg ttc cca ttt aaa	1440		
Tyr Tyr Pro Asp Lys Asn Gly Ile Tyr Asn Gln Arg Phe Pro Phe Lys			
465	470	475	480

act ctc tcc atg gtt acc tca ttc ttt acc aac att tgt gtt tcc tat 1488
 Thr Leu Ser Met Val Thr Ser Phe Phe Thr Asn Ile Cys Val Ser Tyr

485

490

495

cta gcc aag tat cta ttt gaa agt gga acc ttg cct cca aaa tta gat 1536
 Leu Ala Lys Tyr Leu Phe Glu Ser Gly Thr Leu Pro Pro Lys Leu Asp

500

505

510

ata ttt gat gct gtt gtc tca agg cac agt gaa gag aac atg gac aag 1584
 Ile Phe Asp Ala Val Val Ser Arg His Ser Glu Glu Asn Met Asp Lys

515

520

525

acc att cta gtc aga aat gaa aac atc aaa tta aat gaa ctt gca cct 1632
 Thr Ile Leu Val Arg Asn Glu Asn Ile Lys Leu Asn Glu Leu Ala Pro

530

535

540

gta aag cct cga cag agc cta acc ctc agt tca act ttc acc aat aaa 1680
 Val Lys Pro Arg Gln Ser Leu Thr Leu Ser Ser Thr Phe Thr Asn Lys

545

550

555

560

gag gct ctc ctt gat gtt gat tcc agt cca gag gga tct ggg act gaa 1728
 Glu Ala Leu Leu Asp Val Asp Ser Ser Pro Glu Gly Ser Gly Thr Glu

565

570

575

gat aac tta caa tga 1743
 Asp Asn Leu Gln

580

<210> 4

<211> 580

<212> PRT

<213> rat

<400> 4

Met Pro Phe His Val Glu Gly Leu Val Ala Ile Ile Leu Phe Tyr Leu

1 5 10 15

Leu Ile Phe Leu Val Gly Ile Trp Ala Ala Trp Lys Thr Lys Asn Ser

20 25 30

Gly Asn Ala Glu Glu Arg Ser Glu Ala Ile Ile Val Gly Gly Arg Asp

35 40 45

Ile Gly Leu Leu Val Gly Gly Phe Thr Met Thr Ala Thr Trp Val Gly

50 55 60

Gly Gly Tyr Ile Asn Gly Thr Ala Glu Ala Val Tyr Gly Pro Gly Cys

65 70 75 80

Gly Leu Ala Trp Ala Gln Ala Pro Ile Gly Tyr Ser Leu Ser Leu Ile

85 90 95

Leu Gly Gly Leu Phe Phe Ala Lys Pro Met Arg Ser Lys Gly Tyr Val

100 105 110

Thr Met Leu Asp Pro Phe Gln Gln Ile Tyr Gly Lys Arg Met Gly Gly

115 120 125

Leu Leu Phe Ile Pro Ala Leu Met Gly Glu Met Phe Trp Ala Ala Ala

130	135	140	
Ile Phe Ser Ala Leu Gly Ala Thr Ile Ser Val Ile Ile Asp Val Asp			
145	150	155	160
Val Asn Ile Ser Val Ile Val Ser Ala Leu Ile Ala Ile Leu Tyr Thr			
	165	170	175
Leu Val Gly Gly Leu Tyr Ser Val Ala Tyr Thr Asp Val Val Gln Leu			
	180	185	190
Phe Cys Ile Phe Ile Gly Leu Trp Ile Ser Val Pro Phe Ala Leu Ser			
	195	200	205
His Pro Val Val Thr Asp Ile Gly Phe Thr Ala Val His Ala Lys Tyr			
	210	215	220
Gln Ser Pro Trp Leu Gly Thr Ile Glu Ser Val Glu Val Tyr Thr Trp			
	225	230	235
Leu Asp Asn Phe Leu Leu Leu Met Leu Gly Gly Ile Pro Trp Gln Ala			
	245	250	255
Tyr Phe Gln Arg Val Leu Ser Ser Ser Ser Ala Thr Tyr Ala Gln Val			
	260	265	270
Leu Ser Phe Leu Ala Ala Phe Gly Cys Leu Val Met Ala Leu Pro Ala			
	275	280	285
Ile Cys Ile Gly Ala Ile Gly Ala Ser Thr Asp Trp Asn Gln Thr Ala			

290	295	300	
Tyr Gly Phe Pro Asp Pro Lys Thr Lys Glu Glu Ala Asp Met Ile Leu			
305	310	315	320
Pro Ile Val Leu Gln Tyr Leu Cys Pro Val Tyr Ile Ser Phe Phe Gly			
	325	330	335
Leu Gly Ala Val Ser Ala Ala Val Met Ser Ser Ala Asp Ser Ser Ile			
	340	345	350
Leu Ser Ala Ser Ser Met Phe Ala Arg Asn Ile Tyr Gln Leu Ser Phe			
	355	360	365
Arg Gln Asn Ala Ser Asp Lys Glu Ile Val Trp Val Met Arg Ile Thr			
	370	375	380
Val Phe Val Phe Gly Ala Ser Ala Thr Ala Met Ala Leu Leu Thr Lys			
	385	390	395
Thr Val Tyr Gly Leu Trp Tyr Leu Ser Ser Asp Leu Val Tyr Ile Ile			
	405	410	415
Ile Phe Pro Gln Leu Leu Cys Val Leu Phe Ile Lys Gly Thr Asn Thr			
	420	425	430
Tyr Gly Ala Val Ala Gly Tyr Ile Phe Gly Leu Phe Leu Arg Ile Thr			
	435	440	445
Gly Gly Glu Pro Tyr Leu Tyr Leu Gln Pro Leu Ile Phe Tyr Pro Gly			

450	455	460	
Tyr Tyr Pro Asp Lys Asn Gly Ile Tyr Asn Gln Arg Phe Pro Phe Lys			
465	470	475	480
Thr Leu Ser Met Val Thr Ser Phe Phe Thr Asn Ile Cys Val Ser Tyr			
	485	490	495
Leu Ala Lys Tyr Leu Phe Glu Ser Gly Thr Leu Pro Pro Lys Leu Asp			
	500	505	510
Ile Phe Asp Ala Val Val Ser Arg His Ser Glu Glu Asn Met Asp Lys			
	515	520	525
Thr Ile Leu Val Arg Asn Glu Asn Ile Lys Leu Asn Glu Leu Ala Pro			
	530	535	540
Val Lys Pro Arg Gln Ser Leu Thr Leu Ser Ser Thr Phe Thr Asn Lys			
545	550	555	560
Glu Ala Leu Leu Asp Val Asp Ser Ser Pro Glu Gly Ser Gly Thr Glu			
	565	570	575
Asp Asn Leu Gln			
	580		

<210> 5

<211> 1743

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1743)

<223> choline transporter from human

<400> 5

atg gct ttc cat gig gaa gga ctg ata gct atc atc gtg ttc tac ctt 48

Met Ala Phe His Val Glu Gly Leu Ile Ala Ile Ile Val Phe Tyr Leu

1 5 10 15

cta att ttg ctg gtt gga ata tgg gct gcc tgg aga acc aaa aac agt 96

Leu Ile Leu Leu Val Gly Ile Trp Ala Ala Trp Arg Thr Lys Asn Ser

20 25 30

ggc agc gca gaa gag cgc agc gaa gcc atc ata gtt ggt ggc cga gat 144

Gly Ser Ala Glu Glu Arg Ser Glu Ala Ile Ile Val Gly Gly Arg Asp

35 40 45

att ggt tta ttg gtt ggt gga ttt acc atg aca gct acc tgg gtc gga 192

Ile Gly Leu Leu Val Gly Gly Phe Thr Met Thr Ala Thr Trp Val Gly

50 55 60

gga ggg tat atc aat ggc aca gct gaa gca gtt tat gta cca ggt tat 240

Gly Gly Tyr Ile Asn Gly Thr Ala Glu Ala Val Tyr Val Pro Gly Tyr

65 70 75 80

ggc cta gct tgg gct cag gca cca att gga tat tct ctt agt ctg att 288

Gly Leu Ala Trp Ala Gln Ala Pro Ile Gly Tyr Ser Leu Ser Leu Ile

85	90	95	
tta ggt ggc ctg ttc ttt gca aaa cct atg cgt tca aag ggg tat gtg			336
Leu Gly Gly Leu Phe Phe Ala Lys Pro Met Arg Ser Lys Gly Tyr Val			
100	105	110	
acc atg tta gac ccg ttt cag caa atc tat gga aaa cgc atg ggc gga			384
Thr Met Leu Asp Pro Phe Gln Gln Ile Tyr Gly Lys Arg Met Gly Gly			
115	120	125	
ctc ctg ttt att cct gca ctg atg gga gaa atg ttc tgg gct gca gca			432
Leu Leu Phe Ile Pro Ala Leu Met Gly Glu Met Phe Trp Ala Ala Ala			
130	135	140	
att ttc tct gct ttg gga gcc acc atc agc gtg atc atc gat gtg gat			480
Ile Phe Ser Ala Leu Gly Ala Thr Ile Ser Val Ile Ile Asp Val Asp			
145	150	155	160
atg cac att tct gtc atc atc tct gca ctc att gcc act ctg tac aca			528
Met His Ile Ser Val Ile Ile Ser Ala Leu Ile Ala Thr Leu Tyr Thr			
165	170	175	
ctg gtg gga ggg ctc tat tct gtg gcc tac act gat gtc gtt cag ctc			576
Leu Val Gly Gly Leu Tyr Ser Val Ala Tyr Thr Asp Val Val Gln Leu			
180	185	190	
ttt tgc att ttt gta ggg ctg tgg atc agc gtc ccc ttt gca ttg tca			624
Phe Cys Ile Phe Val Gly Leu Trp Ile Ser Val Pro Phe Ala Leu Ser			
195	200	205	

cat cct gca gtc gca gac atc ggg ttc act gct gtg cat gcc aaa tac 672

His Pro Ala Val Ala Asp Ile Gly Phe Thr Ala Val His Ala Lys Tyr

210

215

220

caa aag ccg tgg ctg gga act gtt gac tca tct gaa gtc tac tct tgg 720

Gln Lys Pro Trp Leu Gly Thr Val Asp Ser Ser Glu Val Tyr Ser Trp

225

230

235

240

ctt gat agt ttt ctg ttg ttg atg ctg ggt gga atc cca tgg caa gca 768

Leu Asp Ser Phe Leu Leu Leu Met Leu Gly Gly Ile Pro Trp Gln Ala

245

250

255

tac ttt cag agg gtt ctc tct tct tcc tca gcc acc tat gct caa gtg 816

Tyr Phe Gln Arg Val Leu Ser Ser Ser Ser Ala Thr Tyr Ala Gln Val

260

265

270

ctg tcc ttc ctg gca gct ttc ggg tgc ctg gtg atg gcc atc cca gcc 864

Leu Ser Phe Leu Ala Ala Phe Gly Cys Leu Val Met Ala Ile Pro Ala

275

280

285

ata ctc att ggg gcc att gga gca tca aca gac tgg aac cag act gca 912

Ile Leu Ile Gly Ala Ile Gly Ala Ser Thr Asp Trp Asn Gln Thr Ala

290

295

300

tat ggg ctt cca gat ccc aag act aca gaa gag gca gac atg att tta 960

Tyr Gly Leu Pro Asp Pro Lys Thr Thr Glu Glu Ala Asp Met Ile Leu

305

310

315

320

cca att gtt ctg cag tat ctc tgc cct gtg tat att tct ttc ttt ggt 1008

Pro Ile Val Leu Gln Tyr Leu Cys Pro Val Tyr Ile Ser Phe Phe Gly

325	330	335	
ctt ggt gca gtt tct gct gct gtt atg tca tca gca gat tct tcc atc			1056
Leu Gly Ala Val Ser Ala Ala Val Met Ser Ser Ala Asp Ser Ser Ile			
340	345	350	
ttg tca gca agc tcc atg ttt gca cgg aac atc tac cag ctt tcc ttc			1104
Leu Ser Ala Ser Ser Met Phe Ala Arg Asn Ile Tyr Gln Leu Ser Phe			
355	360	365	
aga caa aat gct tcg gac aaa gaa atc gtt tgg gtt atg cga atc aca			1152
Arg Gln Asn Ala Ser Asp Lys Glu Ile Val Trp Val Met Arg Ile Thr			
370	375	380	
gtg ttt gtg ttt gga gca tct gca aca gcc atg gcc ttg ctg acg aaa			1200
Val Phe Val Phe Gly Ala Ser Ala Thr Ala Met Ala Leu Leu Thr Lys			
385	390	395	400
act gig tat ggg ctc tgg tac ctc agt tct gac ctt gtt tac atc gtt			1248
Thr Val Tyr Gly Leu Trp Tyr Leu Ser Ser Asp Leu Val Tyr Ile Val			
405	410	415	
atc ttc ccc cag ctg ctt tgt gta ctc ttt gtt aag gga acc aac acc			1296
Ile Phe Pro Gln Leu Leu Cys Val Leu Phe Val Lys Gly Thr Asn Thr			
420	425	430	
tat ggg gcc gtg gca ggt tat gtt tct ggc ctc ttc ctg aga ata act			1344
Tyr Gly Ala Val Ala Gly Tyr Val Ser Gly Leu Phe Leu Arg Ile Thr			
435	440	445	

gga ggg gag cca tat ctg tat ctt cag ccc ttg atc ttc tac cct ggc 1392

Gly Gly Glu Pro Tyr Leu Tyr Leu Gln Pro Leu Ile Phe Tyr Pro Gly

450

455

460

tat tac cct gat gat aat ggt ata tat aat cag aaa ttt cca ttt aaa 1440

Tyr Tyr Pro Asp Asp Asn Gly Ile Tyr Asn Gln Lys Phe Pro Phe Lys

465

470

475

480

aca ctt gcc atg gtt aca tca ttc tta acc aac att tgc atc tcc tat 1488

Thr Leu Ala Met Val Thr Ser Phe Leu Thr Asn Ile Cys Ile Ser Tyr

485

490

495

cta gcc aag tat cta ttt gaa agt gga acc ttg cca cct aaa tta gat 1536

Leu Ala Lys Tyr Leu Phe Glu Ser Gly Thr Leu Pro Pro Lys Leu Asp

500

505

510

gta ttt gat gct gtt gtt gca aga cac agt gaa gaa aat atg gat aag 1584

Val Phe Asp Ala Val Val Ala Arg His Ser Glu Glu Asn Met Asp Lys

515

520

525

aca att ctt gtc aaa aat gaa aat att aaa tta gat gaa ctt gca ctt 1632

Thr Ile Leu Val Lys Asn Glu Asn Ile Lys Leu Asp Glu Leu Ala Leu

530

535

540

gtg aag cca cga cag agc atg acc ctc agc tca act ttc acc aat aaa 1680

Val Lys Pro Arg Gln Ser Met Thr Leu Ser Ser Thr Phe Thr Asn Lys

545

550

555

560

gag gcc ttc ctt gat gtt gat tcc agt cca gaa ggg tct ggg act gaa 1728

Glu Ala Phe Leu Asp Val Asp Ser Ser Pro Glu Gly Ser Gly Thr Glu

565

570

575

gat aat tta cag tga

1743

Asp Asn Leu Gln

580

<210> 6

<211> 580

<212> PRT

<213> Homo sapiens

<400> 6

Met Ala Phe His Val Glu Gly Leu Ile Ala Ile Ile Val Phe Tyr Leu

1

5

10

15

Leu Ile Leu Leu Val Gly Ile Trp Ala Ala Trp Arg Thr Lys Asn Ser

20

25

30

Gly Ser Ala Glu Glu Arg Ser Glu Ala Ile Ile Val Gly Gly Arg Asp

35

40

45

Ile Gly Leu Leu Val Gly Gly Phe Thr Met Thr Ala Thr Trp Val Gly

50

55

60

Gly Gly Tyr Ile Asn Gly Thr Ala Glu Ala Val Tyr Val Pro Gly Tyr

65

70

75

80

Gly Leu Ala Trp Ala Gln Ala Pro Ile Gly Tyr Ser Leu Ser Leu Ile

85

90

95

Leu Gly Gly Leu Phe Phe Ala Lys Pro Met Arg Ser Lys Gly Tyr Val

100

105

110

Thr Met Leu Asp Pro Phe Gln Gln Ile Tyr Gly Lys Arg Met Gly Gly

115

120

125

Leu Leu Phe Ile Pro Ala Leu Met Gly Glu Met Phe Trp Ala Ala Ala

130

135

140

Ile Phe Ser Ala Leu Gly Ala Thr Ile Ser Val Ile Ile Asp Val Asp

145

150

155

160

Met His Ile Ser Val Ile Ile Ser Ala Leu Ile Ala Thr Leu Tyr Thr

165

170

175

Leu Val Gly Gly Leu Tyr Ser Val Ala Tyr Thr Asp Val Val Gln Leu

180

185

190

Phe Cys Ile Phe Val Gly Leu Trp Ile Ser Val Pro Phe Ala Leu Ser

195

200

205

His Pro Ala Val Ala Asp Ile Gly Phe Thr Ala Val His Ala Lys Tyr

210

215

220

Gln Lys Pro Trp Leu Gly Thr Val Asp Ser Ser Glu Val Tyr Ser Trp

225

230

235

240

Leu Asp Ser Phe Leu Leu Leu Met Leu Gly Gly Ile Pro Trp Gln Ala

245

250

255

Tyr Phe Gln Arg Val Leu Ser Ser Ser Ser Ala Thr Tyr Ala Gln Val
260 265 270

Leu Ser Phe Leu Ala Ala Phe Gly Cys Leu Val Met Ala Ile Pro Ala
275 280 285

Ile Leu Ile Gly Ala Ile Gly Ala Ser Thr Asp Trp Asn Gln Thr Ala
290 295 300

Tyr Gly Leu Pro Asp Pro Lys Thr Thr Glu Glu Ala Asp Met Ile Leu
305 310 315 320

Pro Ile Val Leu Gln Tyr Leu Cys Pro Val Tyr Ile Ser Phe Phe Gly
325 330 335

Leu Gly Ala Val Ser Ala Ala Val Met Ser Ser Ala Asp Ser Ser Ile
340 345 350

Leu Ser Ala Ser Ser Met Phe Ala Arg Asn Ile Tyr Gln Leu Ser Phe
355 360 365

Arg Gln Asn Ala Ser Asp Lys Glu Ile Val Trp Val Met Arg Ile Thr
370 375 380

Val Phe Val Phe Gly Ala Ser Ala Thr Ala Met Ala Leu Leu Thr Lys
385 390 395 400

Thr Val Tyr Gly Leu Trp Tyr Leu Ser Ser Asp Leu Val Tyr Ile Val
405 410 415

Ile Phe Pro Gln Leu Leu Cys Val Leu Phe Val Lys Gly Thr Asn Thr

420

425

430

Tyr Gly Ala Val Ala Gly Tyr Val Ser Gly Leu Phe Leu Arg Ile Thr

435

440

445

Gly Gly Glu Pro Tyr Leu Tyr Leu Gln Pro Leu Ile Phe Tyr Pro Gly

450

455

460

Tyr Tyr Pro Asp Asp Asn Gly Ile Tyr Asn Gln Lys Phe Pro Phe Lys

465

470

475

480

Thr Leu Ala Met Val Thr Ser Phe Leu Thr Asn Ile Cys Ile Ser Tyr

485

490

495

Leu Ala Lys Tyr Leu Phe Glu Ser Gly Thr Leu Pro Pro Lys Leu Asp

500

505

510

Val Phe Asp Ala Val Val Ala Arg His Ser Glu Glu Asn Met Asp Lys

515

520

525

Thr Ile Leu Val Lys Asn Glu Asn Ile Lys Leu Asp Glu Leu Ala Leu

530

535

540

Val Lys Pro Arg Gln Ser Met Thr Leu Ser Ser Thr Phe Thr Asn Lys

545

550

555

560

Glu Ala Phe Leu Asp Val Asp Ser Ser Pro Glu Gly Ser Gly Thr Glu

565

570

575

Asp Asn Leu Gln

580

[Brief Explanation of the Drawings]

[Fig. 1]

This is a view showing the result of [^3H] choline uptake of oocytes from *Xenopus* of the present invention being injected with *C. elegans* cho-1 (C48D1.3 cRNA) or water.

[Fig. 2]

This is a view showing the result of the effect of Na^+ on choline uptake of oocytes from *Xenopus* of the present invention being injected with *C. elegans* cho-1 (C48D1.3 cRNA) or water.

[Fig. 3]

This is a view showing the result of the HC3-induced inhibition of choline uptake of oocytes from *Xenopus* of the present invention being injected with *C. elegans* cho-1 (C48D1.3 cRNA) or water.

[Fig. 4]

This is a view showing amino acid sequences of rat CHT1 and *C. elegans* CHO-1 of the present invention respectively.

[Fig. 5]

This is a view showing the distribution of neurons expressing cho-1::gfp of the present invention in the nervous system of *C. elegans*.

[Fig. 6]

This is a view showing the phylogenetic tree of Na^+ -dependent glucose transporter family.

[Fig. 7]

This is a view showing an expected topology of rat CHT1

of the present invention.

[Fig. 8]

This is a view showing the result of Northern blot analysis of CHT1 mRNA transcript in rat tissue of the present invention.

[Fig. 9]

This is a view showing the result of *in situ* hybridization analysis of CHT1 transcript in a rat brain of the present invention.

[Fig. 10]

This is a view showing the result of *in situ* hybridization analysis of CHT1 transcript in a spinal cord of the present invention.

[Fig. 11]

This is a view showing the result of [^3H] choline uptake of oocytes from *Xenopus* of the present invention being injected CHT1 cRNA of the present invention or water.

[Fig. 12]

This is a view showing the effect of choline concentration on choline uptake in CHT1 of the present invention.

[Fig. 13]

This is a view showing the result of HC3-induced inhibition of choline uptake of CHT1 of the present invention.

[Fig. 14]

This is a view showing the result of Na^+ - and Cl^- -dependent choline uptake of CHT1 of the present invention.

[Fig. 15]

This is a view showing the result of [^3H] HC3 binding to the membrane prepared from COS7 cells being introduced with CHT1 cDNA of the present invention or vector pcDNA 3.1 separately.

[Fig. 16]

This is a view showing the result of saturation analysis of specific [^3H] HC3 binding to the membrane prepared from COS7 cells being introduced with CHT1 cDNA of the present invention or vector pcDNA 3.1 separately.

[Fig. 17]

This is a view showing the result of displacement of specific [^3H] HC3 binding by HC3 of the present invention, choline (Cho), acetylcholine (ACh).

[Name of Document] ABSTRACT


[Abstract]

[The Object] The object of the present invention is to provide a protein having high-affinity choline transporter activity which is important physiologically, a gene encoding the protein, and a method of screening a material promoting the high-affinity choline transporter activity with the use of the same, and the like.


[Solving Means] By examining high-affinity choline uptake activity of Na⁺-dependent transporter cDNA deduced from the genomic sequence of a nematode *C.elegans* in a *Xenopus* oocyte expression system, the cDNA (cho-1) of nematode high-affinity choline transporter is identified. Then the cDNA (CHT1) of rat high-affinity choline transporter is cloned from rat spinal cord by using the homology of a base sequence to this cDNA as an index. Similarly, the cDNA of human high-affinity choline transporter is cloned from human genome.

[Selected Drawing] Fig. 4


[Fig. 1]



[Fig. 2]



[Fig. 3]




[Fig. 4]


CHT1	MPFHVEGVVAIVFYVLIIVGIWAAMKTKNS-----GVAEERSEATVVGGRDGLLVGGF	56
cht-1	-MADLGVVAIVFYVLIIVGIWAGRKSKSSKELESAGAAIEVVLAGRNLGTLVGIF	59
I		
CHT1	TMTATWVGGGYINGTAEAYGPGCGLAWAQAPGYSLSLIGGLFAKPMRSKGYTMLD	116
cht-1	TMTATWVGGAINGTAEALYNGGLLGCQAPVGYASLVGGLFAKPMREKGYTMLD	117
II		
CHT1	PFQIYGKRYGGLIPALMGEMFWAAAIISALGATISVIIDVDYNISVIVSALIAIYT	176
cht-1	PFQIKYGORIGGLIPALLGETFWTAALISALGATISVIGDYNASVTSACIAMYT	177
III		
IV		
CHT1	IVGGLYSVAYTDVVQLFCIFGLWISVPFALSHPVVTDIGFTAVHAKYQSPWLGITIES-V	235
cht-1	ITGGYYAVAYTDVVQLFCIFVGLWICVPAAVHDGAKDISRNAG-----DWIGEIGGFK	231
V		
CHT1	EVYTWEDNLLLGGIPWQAYFQRLSSSATYAQVLSFAAFGCLVMAIPAICIGATG	295
cht-1	ETSLWIDCLLLGGIPWQVYFQRLSSKTHGAQTLSEFVAGVGCILMAIPPALIGATA	291
VI		
VII		
CHT1	ASTDWNQTAYGFPDPKTKEEAD-----MTLPVLEQYLCPVYISFGLGAVSAAMSSAD	349
cht-1	RNTDWRMTDYSPWNGTKVESIPPKDRNMVPLVLEQYLTPIRWAFIIGLGAUSAAMSSAD	351
VIII		
CHT1	SSLSSASSMFARNIYQLSFRONASDKEIYWMRIIVVFGASATAMALLTKIVYGLWYLS	409
cht-1	SSVLSAASSMFAINIKLITRPEASEKEVITVMRIATCVGIMATIMALTIOSYGLWYLC	411
IX		
CHT1	SDLVYIIFPQLLCVIFIKGINTYGAAGYIFGLFLRIIGGEPYLYLQPIFYPGYYPDK	469
cht-1	ADLVYIIFPQLLCVYMPRNTYGSAGYAVGLVLRIGGEPVLSLPATFHYPWT-D	469
X		
XI		
CHT1	NGIYNQRFPFKTLNMTISFTNICVSYLAKYLFESGTLPPKLDITDAVVSRI--HSEENM	526
cht-1	G---VOYFPRITAMSSMATIYIVSIOSEKLFKSGRLSPEDVMGCVNIPIDVPLPS	526
XII		
CHT1	DKITLVRNENIKLNELAPVKPRQSITLSSFTINKEALLDVDSSPEGSGTIDNLQ	580
cht-1	DVSEAVSSE--TLNMAKAPNGTPAPVHPNQPSDENITLHPYSDQSYSTNSN--	576




[Fig. 5]




[Fig. 6]





[Fig. 7]




[Fig. 8]




[Fig. 9]




[Fig. 10]




[Fig. 11]




[Fig. 12]





[Fig. 13]




[Fig. 14]



[Fig. 15]



[Fig. 16]



[Fig. 17]

